公司資料
Longeveron 股價、新聞與催化劑
- 股票代碼:
- LGVN
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
0.84 USD (+2.02%)
收盤價
最後更新: 2026年8月21日
24M USD
市值
股價為何變動
The latest monitored company update is “Longeveron Announces 1-for-10 Reverse Stock Split.” The corresponding closing-price reaction is not yet available.
公司概覽
Regenerative Medicine Company
Longeveron develops allogeneic cellular therapies for rare pediatric and chronic aging-related conditions.
Laromestrocel
Laromestrocel, formerly Lomecel-B, is manufactured from bone marrow-derived medicinal signaling cells obtained from young healthy adult donors.
Hypoplastic Left Heart Syndrome
The ELPIS program evaluates laromestrocel as an adjunct to staged surgery in infants with hypoplastic left heart syndrome, an orphan pediatric condition.
Additional Regenerative Applications
The company is also exploring laromestrocel in aging-related and neurological conditions where inflammation and impaired tissue repair may contribute to disease.
未來催化劑
- Topline results from the Phase 2b ELPIS II study in hypoplastic left heart syndrome are expected in August 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。